摘要
目的:观察肾康注射液治疗慢性肾脏病(Chronic Kidney Disease,CKD)3~4期的临床效果。方法:将江门市新会区中医院2015-2020年收治的72例CKD3~4期患者纳入临床试验,随机分为观察组和对照组,每组36例。对照组患者给予现代医学治疗,观察组在此基础上予肾康注射液40 mL+5%葡萄糖溶液(或0.9%氯化钠溶液)100 mL静滴,每日1次,疗程14 d。观察记录患者治疗前后的血肌酐(Serum Creatinine,Scr)、尿素氮(Blood Ure Nitrogen,BUN)、肌酐清除率(Creatinine Clearance,Ccr)指标,并比较分析其变化情况及治疗效果。结果:治疗后,观察组Scr、BUN、Ccr均较前有明显改善,差异有统计学意义(P<0.05)。对照组Scr、Ccr较治疗前略有降低,但差异无统计学意义(P>0.05),BUN较前有所改善(P<0.05);治疗后,观察组Scr、BUN、Ccr改善情况均优于对照组,差异有统计学意义(P<0.05)。治疗后,两组中医辨证积分较前都有降低,差异有统计学意义(P<0.05)。观察组总有效率为97.2%(35/36),相较于对照组的总有效率36.1%(31/36),有统计学差异(P<0.05)。结论:肾康注射液可降低Scr和BUN,提高Ccr,可改善CKD3~4期患者临床症状,值得临床推广应用。
Objective:To observe the efficacy of Shenkang injection(肾康注射液)in the treatment of chronic kidney disease(CKD,stage 3-4).Methods:72 cases of CKD(stage 3-4)patients were randomly divided into the observation group(36 patients)and the control group(36 patients).The patients in the control group were treated with modern medicine,while the patients in the observation group were treated with Shenkang injection 40 mL+5%GS(or 0.9%NS)100ml intravenous drip once a day for 14 days on the basis of modern medicine.The indexes of serum creatinine(Scr),blood urea nitrogen(BUN)and creatinine clearance rate(Ccr)before and after treatment were observed and recorded,and the changes and therapeutic effects were compared and analyzed.Results:After treatment,Scr,BUN and Ccr in the observation group were obviously improved,which was with statistically significant difference(P<0.05).Compared with those before treatment,Scr and Ccr in the control group decreased slightly,there was no statistical difference(P>0.05).BUN was improved partly(P<0.05).After treatment,the improvement of Scr,BUN and Ccr in the observation group was better than that in the control group,which was with statistically significant difference(P<0.05).After treatment,the TCM syndrome differentiation scores of the two groups were lower than those before treatment,which was with statistical significance(P<0.05).The total effective rate of the observation group was 97.2%(35/36),which was significantly higher than that of the control group(36.1%,31/36)(P<0.05).Conclusion:Shenkang injection can reduce Scr and BUN,increase Ccr,and relieve the clinical symptoms of CKD3-4 patients,which is worthy of clinical application.
出处
《中医临床研究》
2021年第24期86-87,93,共3页
Clinical Journal Of Chinese Medicine
关键词
肾康注射液
慢性肾脏病3~4期
血肌酐
肌酐清除率
临床疗效
Shenkang injection
Chronic kidney disease stage 3-4
Serum creatinine
Creatinine clearance rate
Clinical efficacy
